## **Special Issue**

## Personalized Diagnosis and Treatment of Heart Failure

## Message from the Guest Editor

Heart failure (HF) is a highly prevalent clinical syndrome with serious morbidity and mortality. Acute heart failure (AHF) is the main cause of hospital admission for people aged 65 years or older. In this particular population, even when adhering to clinical guidelines for treatment. other comorbid conditions should be taken into consideration. Thus, treatment should be discussed individually with patients, accounting for both the actual recommendations and personalized medical approaches, such as genetic predispositions, individual responsiveness to treatments, and lifestyle modifications. We seek original articles and reviews that not only cover the latest advancements in standard treatment protocols but also emphasize the importance of integrating personalized medicine in the management of HF to improve patient outcomes and quality of life.

## **Guest Editor**

Dr. Manuel Méndez Bailon

- 1. Internal Medicine Department, Hospital Universitario Clínico San Carlos, 28040 Madrid, Spain
- 2. School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
- 3. Instituto de Investigación Sanitaria Hospital Clínico San Carlos, 28040 Madrid, Spain

## Deadline for manuscript submissions

25 March 2026



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/242936

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

#### **Editor-in-Chief**

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

